You searched for Athersys

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature

March 3, 2024 / Professor Paul Knoepfler, Ph.D. / 1 Comment

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough […]

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

October 3, 2023 / Professor Paul Knoepfler, Ph.D. / 11 Comments

Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative

June 26, 2022 / Professor Paul Knoepfler, Ph.D. / 1 Comment

It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the

Weekly reads: teratoma in iPSC trial, Piero Anversa & friends, Athersys, China Initiative Read More »

Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain

August 9, 2020 / Professor Paul Knoepfler, Ph.D. / 3 Comments

What are you reading these days and does it include topics like cell therapies for COVID-19, ALS, regenerative potential of fibroblasts, and why Zoom meetings are so tiring for the brain? I cover those topics and more below with recommended reads including papers and media items. Here’s last week’s recommended reads. Here’s to fibroblasts, which

Athersys & Mesoblast stem cells for COVID-19?

March 10, 2020 / Professor Paul Knoepfler, Ph.D. / 7 Comments

Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients

Athersys & Mesoblast stem cells for COVID-19? Read More »

About that Athersys stem cell stroke clinic trial PR…

February 19, 2016 / Professor Paul Knoepfler, Ph.D. / 12 Comments

There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers

About that Athersys stem cell stroke clinic trial PR… Read More »

Interview with Gil Van Bokkelen of Athersys

May 20, 2013 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of

Interview with Gil Van Bokkelen of Athersys Read More »

Weekly reads: Chinese CRISPR biotechs, cultured meat war, MSCs for Alzheimer’s

March 23, 2025 / Professor Paul Knoepfler, Ph.D. / 6 Comments

HuidaGene Therapeutics, Chinese CRISPR biotech

Chinese CRISPR research continues to grow and this includes interesting CRISPR biotech firms. Some here in the U.S. worry that American gene editing firms could be lagging behind. Especially over the past year, investors and even some scientists have voiced frustration. U.S. gene editing firms like Editas have been struggling for years. Its stock is

Weekly reads: Chinese CRISPR biotechs, cultured meat war, MSCs for Alzheimer’s Read More »

Grading my 20 stem cell & regenerative medicine predictions for 2024

December 24, 2024 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Did you predict the major events in the stem cell and regenerative medicine field this year? I tried and today’s post are the grades on my predictions. Prediction is a key part of being a scientist even if we may not think about it that much. For instance, we have to try to predict what

Grading my 20 stem cell & regenerative medicine predictions for 2024 Read More »

20 stem cell & regenerative medicine predictions for 2024

January 3, 2024 / Professor Paul Knoepfler, Ph.D. / 4 Comments

Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please

20 stem cell & regenerative medicine predictions for 2024 Read More »

Search Results for: Athersys